Intravitreal MTX and ZR Regimen in Newly Diagnosed PVRL
- Status
- UNKNOWN
- Phase
- PHASE2
Clinical Trials Related to Rituximab
Related studies linked through entity extraction aliases.
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1
Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis
- Status
- RECRUITING
- Phase
- PHASE3
Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma
- Status
- SUSPENDED
- Phase
- PHASE1
A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE3
Safe Accelerated Venetoclax Escalation in CLL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL
- Status
- UNKNOWN
- Phase
- PHASE2
Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2/PHASE3
To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)
- Status
- WITHDRAWN
- Phase
- PHASE3
A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)
- Status
- TERMINATED
- Phase
- PHASE1
Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing Briquilimab
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Efficacy and Safety of Rituximab in the First Episode of Pediatric Idiopathic Nephrotic Syndrome
- Status
- COMPLETED
- Phase
- PHASE2
Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies
- Status
- WITHDRAWN
- Phase
- EARLY_PHASE1
Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Venetoclax, Rituximab and Ibrutinib in TN Patients With CLL Undetectable Minimal Residual Disease (uMRD) in Treatment-naïve Patients With Chronic Lymphocytic Leukemia (CLL)
- Status
- RECRUITING
- Phase
- PHASE2